|
Convertible Securities (Details) (USD $)
|
0 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 24, 2016
|
Sep. 30, 2013
|
Apr. 30, 2013
|
Feb. 28, 2013
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2013
Series B Preferred Stock [Member]
|
Dec. 31, 2012
Series B Preferred Stock [Member]
|
Jul. 31, 2012
Series B Preferred Stock [Member]
Platinum [Member]
|
May 31, 2011
Series B Preferred Stock [Member]
Platinum [Member]
|
Dec. 31, 2013
Series B Preferred Stock [Member]
Platinum [Member]
|
Dec. 31, 2013
Series B Preferred Stock [Member]
Platinum [Member]
|
Sep. 30, 2013
Series B Preferred Stock [Member]
Platinum [Member]
|
Jul. 31, 2013
Series B Preferred Stock [Member]
Platinum [Member]
|
Nov. 30, 2012
Series B Preferred Stock [Member]
Platinum [Member]
|
Jun. 30, 2010
Series C Preferred Stock [Member]
Bupp Investors [Member]
|
Jun. 30, 2013
Common Stock [Member]
|
Dec. 31, 2013
Common Stock [Member]
|
Jul. 31, 2012
Common Stock [Member]
Platinum [Member]
|
May 31, 2011
Common Stock [Member]
Platinum [Member]
|
Dec. 31, 2012
Common Stock [Member]
Bupp Investors [Member]
|
Dec. 31, 2013
Common Stock [Member]
Platinum [Member]
|
Sep. 30, 2013
Common Stock [Member]
Platinum [Member]
|
Jul. 31, 2013
Common Stock [Member]
Platinum [Member]
|
Nov. 30, 2012
Common Stock [Member]
Platinum [Member]
|
Jun. 30, 2013
Preferred Stock [Member]
|
Dec. 31, 2013
Preferred Stock [Member]
|
Dec. 31, 2013
Series GG Warrants [Member]
|
Jun. 30, 2010
Series B Preferred Stock [Member]
|
Dec. 31, 2013
Platinum Montaur Life Sciences Llc Credit Facility [Member]
|
Dec. 31, 2013
Platinum Montaur Life Sciences Llc Credit Facility [Member]
Series X Warrants And Series Aa Warrants [Member]
|
Jun. 30, 2013
Platinum Montaur Life Sciences Llc Credit Facility [Member]
Series X Warrants And Series Aa Warrants [Member]
|
Dec. 31, 2013
Maximum [Member]
|
Jun. 30, 2013
Maximum [Member]
Series B Preferred Stock [Member]
|
Dec. 31, 2013
Maximum [Member]
Platinum Montaur Life Sciences Llc Credit Facility [Member]
|
Dec. 31, 2013
Minimum [Member]
|
Jun. 30, 2013
Minimum [Member]
Series B Preferred Stock [Member]
|
|
| Debt Instrument [Line Items] | ||||||||||||||||||||||||||||||||||||||
| Conversion of Stock, Shares Converted | 3,063 | 917 | 447 | 710.9 | 580 | 10,000 | ||||||||||||||||||||||||||||||||
| Convertible Preferred Stock, Terms of Conversion | 3,226,000 | 32,700,000 | ||||||||||||||||||||||||||||||||||||
| Convertible Preferred Stock, Aggregate Shares Issued upon Conversion | 1,300,000 | |||||||||||||||||||||||||||||||||||||
| Debt Instrument, Interest Rate, Stated Percentage | 2.80% | 10.00% | ||||||||||||||||||||||||||||||||||||
| Warrants, exercise price | 3.39 | 2.10 | 3.83 | 1.97 | ||||||||||||||||||||||||||||||||||
| Warrants, expiration date | Sep. 24, 2016 | Dec. 29, 2016 | ||||||||||||||||||||||||||||||||||||
| Issued stock in connection with public offerings, net of costs, shares | 10,563,381 | 2,100,000 | 1,542,389 | 918 | 1,000 | |||||||||||||||||||||||||||||||||
| Convertible preferred stock, shares issuable upon conversion | 3,226,000 | 24,737,550 | ||||||||||||||||||||||||||||||||||||
| Loss on extinguishment of debt | $ (1,372,266) | $ 0 | $ 0 | |||||||||||||||||||||||||||||||||||
| Conversion of Stock, Shares Issued | 10,016,010 | 2,998,590 | 1,461,690 | 2,324,643 | 1,896,600 | |||||||||||||||||||||||||||||||||
| Shares exchanged | 3,001,860 | |||||||||||||||||||||||||||||||||||||
| Preferred Stock, Shares Outstanding | 7,565 | 6,938 | ||||||||||||||||||||||||||||||||||||
| Debt instrument, maximum borrowing amount | 35,000,000 | |||||||||||||||||||||||||||||||||||||
| Debt instrument, spread on U.S. Prime Rate | 6.75% | |||||||||||||||||||||||||||||||||||||
| Debt instrument, effective interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
| Non-cash interest expense related to debt | 765,000 | 545,000 | 4,000 | |||||||||||||||||||||||||||||||||||
| Conversion of Series B preferred stock to common stock, shares | 2,364.9 | 2,364.9 | ||||||||||||||||||||||||||||||||||||
| Number of common shares underlying Series B Preferred Stock | 7,733,223 | 7,733,223 | ||||||||||||||||||||||||||||||||||||
| Shares conversion, number of common stock equivalent to each preferred stock | 3,270 | 3,270 | ||||||||||||||||||||||||||||||||||||
| MinimumGrossCashProceedsFromPublicOfferingOfCommonStockForAutomaticConversion | $ 10,000,000 | |||||||||||||||||||||||||||||||||||||
| Share Price | $ 7.00 | $ 5.00 | ||||||||||||||||||||||||||||||||||||
| Conversion Of Stock, Threshold, Consecutive Trading Days | 180 | |||||||||||||||||||||||||||||||||||||